PeLeMed is a South Korean oncology biotechnology company founded in 2019 and based on the GIST campus in Gwangju, with an office at Seoul National University's College of Pharmacy. It develops targeted cancer therapies through precision drug design and an AI-driven discovery platform, focusing on cancers that resist existing treatments. Its lead candidate PLM-102, a next-generation FLT3/RET dual inhibitor for acute myeloid leukemia, is in a multi-center Phase 1 trial managed by MD Anderson Cancer Center; the company was co-founded by GIST professor Kim Yong Cheol.
1
Round
1
Industry
4
Tags
Sep 9, 2026
Latest raise
Funding activity · 1 round
Sep 9, 2026
KRW 5B
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
